newsfilter
← Latest News
Earnings Call Transcripts·

CARDIFF ONCOLOGY - UBS Global Biopharma Conference Webcast - CARDIFF ONCOLOGY INC

  • Financial Performance:

    • Reported cash balance of approximately $34 million as of the end of the third quarter.
    • Current cash runway is projected to extend through the end of Q3 2027.
    • No revenue, earnings, or profit margin data available as the company is a clinical-stage biopharmaceutical entity; focus remains on R&D execution and capital preservation.
    • Funding status is a primary operational metric, with the company actively seeking capital to initiate Phase 3 trials.
  • Guidance and Future Outlook:

    • Aiming to initiate the Phase 3 registrational trial (CARDF003) in the first quarter of 2027.
    • Planning a potential staged initiation of the trial to manage resources effectively.
    • The company is targeting two potential regulatory pathways: full approval based on Progression-Free Survival (PFS) and accelerated approval based on Overall Response Rate (ORR) and durability.
    • Long-term goal is to establish a new treatment paradigm for metastatic colorectal cancer (mCRC) where no significant innovation has occurred in over 20 years.
  • Business Segments and Product Lines:

    • Lead Asset: Onvansertib, a selective and tolerable PLK1 inhibitor, being developed for RAS-mutated diseases.
    • Primary Indication: First-line treatment of metastatic colorectal cancer (mCRC) with pan-RAS mutations (NRAS, KRAS).
    • Clinical Trial Status: The ongoing Phase 2 randomized controlled trial (CARDF004) is comparing Onvansertib (30mg) + FOLFIRI + Bevacizumab against standard of care; data remains immature for median PFS in the treatment arm but shows compelling trends.
    • Secondary Indications: Promising monotherapy signals observed in relapsed/refractory chronic myelomonocytic leukemia (CMML) and early signals in small cell lung cancer.
    • Regulatory Milestones: Received Fast-Track designation for the mCRC indication this past Friday; received Orphan Drug Designation for both CMML and small cell lung cancer.
    • Preferred Regimen: Data supports the combination of Onvansertib (30mg) with FOLFIRI (irinotecan-based) + Bevacizumab as the optimal regimen for Phase 3, distinct from FOLFOX.
  • Market and Competitive Landscape:

    • Targets approximately 50% of mCRC patients who harbor RAS mutations, a population historically treated only with chemotherapy and Bevacizumab.
    • Addresses a high unmet need with no approved targeted therapies for this specific population in the last 20 years.
    • Competitors in the first-line setting are primarily targeting MSS (microsatellite stable) populations with PD-1/VEGF or PD-L1/VEGF inhibitors, or specific G12C mutations, leaving the broader pan-RAS population largely unaddressed.
    • The company claims a unique mechanism of action (synthetic lethality) via PLK1 inhibition in RAS-mutated cancers, which are dependent on PLK1 for cell division.
  • Risks and Challenges:

    • Clinical Risk: Reliance on the success of a single Phase 3 trial design; failure to replicate Phase 2 efficacy trends would jeopardize commercial viability.
    • Financial Risk: Limited cash runway ending Q3 2027 necessitates successful capital raising before Phase 3 initiation.
    • Regulatory Risk: While Fast-Track is granted, full approval hinges on statistically significant PFS data in Phase 3, and accelerated approval requires compelling ORR data.
    • Competition: While currently unaddressed, the space remains attractive, potentially drawing interest from larger competitors if clinical data validates the target.
    • Operational Risk: Delays in trial initiation due to funding or regulatory interactions could impact the timeline to market.
  • Management Commentary and Tone:

    • CEO Mani Mohindru expressed high confidence in the data, describing the Phase 2 results as "compelling" and a "clear winner" compared to standard of care.
    • Tone is optimistic and forward-looking, emphasizing the transformative potential of the drug to change clinical practice.
    • Management highlighted strong regulatory alignment, noting successful End of Phase 2 meetings with the FDA regarding dose selection and trial design.
    • Emphasis placed on the drug's tolerability, which enables long-term first-line administration.
  • Analyst Questions and Answers:

    • No formal Q&A session transcript was provided in the source text; the segment was a CEO presentation.
    • Implicit Q&A: Addressed via presentation why Onvansertib pairs better with FOLFIRI (irinotecan) than FOLFOX (oxaliplatin), citing synergistic inhibition of HIF-1-alpha and DNA damage repair mechanisms specific to irinotecan and PLK1 inhibition.
    • Implicit Q&A: Addressed the difference in patient selection, confirming the trial will be "pan-RAS" (all RAS mutations) rather than restricted to specific subtypes like G12C.
  • Other Key Points:

    • Mechanism of Action: Onvansertib inhibits PLK1, a target critical for DNA repair in RAS-mutated cells; it synergizes with irinotecan (topoisomerase 1 inhibitor) which damages DNA, creating a "two-punch" effect.
    • Data Highlights: Phase 2 showed ~70% ORR vs. ~42% for standard of care; patients on the 30mg arm remained on treatment >21 months; several patients achieved sufficient tumor shrinkage for curative surgery.
    • Geographic Scope: Currently engaging with US FDA and European regulators; awaiting feedback from Europe regarding potential approval pathways.
    • Collaborations: Working with a selected Contract Research Organization (CRO) to facilitate trial initiation.
Company
CARDIFF ONCOLOGY INC
Keywords
CARDIFF ONCOLOGY INC